Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are functionally active in an ex vivo flow model of thrombosis

Blood

Volumn 114, Issue 24, 2009, Pages 5044-5051

  Salles, Isabelle I ^a   Thijs, Tim ^a   Brunaud, Christine ^b,c   De Meyer, Simon F ^a   Thys, Johan ^d   Vanhoorelbeke, Karen ^a   Deckmyn, Hans ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ThromboGenics NV   (Belgium)

^c GSK   (Belgium)

^d Groeninge Ziekenhuis   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DUAL SPECIFICITY PHOSPHATASE 2; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 16N7C2; MONOCLONAL ANTIBODY 6B4; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SHEAR RATE; THROMBOCYTOPOIESIS; THROMBOSIS; THROMBUS; UMBILICAL CORD BLOOD; ANIMAL; CELL DIFFERENTIATION; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOLOGY; DISEASE MODEL; METABOLISM; METHODOLOGY; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE;

ANIMALS; ANTIGENS, CD34; BLOOD PLATELETS; CELL DIFFERENTIATION; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; THROMBOPOIESIS; THROMBOSIS;

EID: 73949140788     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-205989     Document Type: Article

References (49)

1. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-MpL ligand thrombopoietin. Nature. 1994;369:568-571.
2. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008;111:981-986.
3. + megakaryocytic cells. Haematologica. 2000;85:25-30.
4. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol. 2006;134:453-466.
5. Bruno S, Gunetti M, Gammaitoni L, et al. In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: rapid and transient megakaryocyte reconstitution. Haematologica. 2003;88:379-387.
6. Sun L, Tan P, Yap C, et al. In vitro biological characteristics of human cord blood-derived megakaryocytes. Ann Acad Med Singapore. 2004;33:570-575.
7. Tomer A. Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes. Blood. 2004;104:2722-2727.
8. Balduini A, d'Apolito M, Arcelli D, et al. Cord blood in vitro expanded CD41 cells: identification of novel components of megakaryocytopoiesis. J Thromb Haemost. 2006;4:848-860.
9. Liu XL, Yuan JY, Zhang JW, Zhang XH, Wang RX. Differential gene expression in human hematopoietic stem cells specified toward erythroid, megakaryocytic, and granulocytic lineage. J Leukocyte Biol. 2007;82:986-1002.
10. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, et al. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood. 2007;109:3260-3269.
11. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood. 1995;85:402-413.
12. + progenitor cells to study transgenes in the platelet environment. Circ Res. 2004;95:e36-e44.
13. Gillitzer A, Peluso M, Laugwitz KL, et al. Retroviral infection and selection of culture-derived platelets allows study of the effect of transgenes on platelet physiology ex vivo and on thrombus formation in vivo. Arterioscler Thromb Vasc Biol. 2005;25:1750-1755.
14. Wei MX, Yang Y, Ge YC, Xu P. Functional characterization of hNUDC as a novel accumulator that specifically acts on in vitro megakaryocytopoiesis and in vivo platelet production. J Cell Biochem. 2006;98:429-439.
15. Sullenbarger B, Bahng JH, Gruner R, Kotov N, Lasky LC. Prolonged continuous in vitro human platelet production using three-dimensional scaffolds. Exp Hematol. 2009;37:101-110.
16. Lapidot T, Fajerman Y, Kollet O. Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. J Mol Med. 1997;75:664-673.
17. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180-191.
18. Angelopoulou M, Novelli E, Grove JE, et al. Co-transplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol. 2003;31:413-420.
19. Angelopoulou MK, Rinder H, Wang C, Burtness B, Cooper DL, Krause DS. A preclinical xeno-transplantation animal model to assess human hematopoietic stem cell engraftment. Transfusion. 2004;44:555-566.
20. + cells. Stem Cells. 2004;22:135-143.
21. + cells, thrombopoietin-amplified in clinical grade serum-free culture. Exp Hematol. 2008;36:244-252.
22. + cells provides an in vivo model for human megakaryocytopoiesis and platelet production. Blood. 2001;97:1635-1643.
23. Perez LE, Alpdogan O, Shieh JH, et al. Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Exp Hematol. 2004;32:300-307.
24. + cells. Eur J Haematol. 2006;78:123-130.
25. Tijssen MR, van Hennik PB, di Summa F, Zwaginga JJ, van der Schoot CE, Voermans C. Transplantation of human peripheral blood CD34-positive cells in combination with ex vivo generated megakaryocytes results in fast platelet formation in NOD/SCID mice. Leukemia. 2008;22:203-208.
26. + cells in NOD/Shi-scid mice. Stem Cells. 2000;18:204-213.
27. + cord blood cells with thrombopoietin (TPO) accelerates platelet engraftment in a NOD/SCID mouse model. Exp Hematol. 2006;34:943-950.
28. Schipper LF, van Hensbergen Y, Fibbe WE, Brand A. A sensitive quantitative single-platform flow cytometry protocol to measure human platelets in mouse peripheral blood. Transfusion. 2007;47:2305-2314.
29. De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H. Antiplatelet drugs. Br J Haematol. 2008;142:515-528.
30. Boylan B, Berndt MC, Kahn ML, Newman PJ. Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of antihuman platelet agents. Blood. 2006;108:908-914.
31. Chen J, Tan K, Zhou H, et al. Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies. Nat Biotechnol. 2008;26:114-119.
32. Cauwenberghs N, Vanhoorelbeke K, Vauterin S, et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibα reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibα. Blood. 2001;98:652-660.
33. Fontayne A, Meiring M, Lamprecht S, et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost. 2008;100:670-677.
34. Deckmyn H, Stanssens P, Hoet B, et al. An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function. Br J Haematol. 1994;87:562-571.
35. Cauwenberghs N, Meiring M, Vauterin S, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol. 2000;20:1347-1353.
36. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol. 2002;22:323-328.
37. Nonne C, Lenain N, Hechler B, et al. Importance of platelet phospholipase Cγ2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol. 2005;25:1293-1298.
38. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998;94:657-666.
39. 3. J Clin Invest. 2005;115:3363-3369.
40. Bergmeier W, Piffath CL, Goerge T, et al. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A. 2006;103:16900-16905.
41. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106:1901-1910.
42. 2 microglobulin-null mice. J Clin Invest. 2001;107:199-206.
43. + cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci U S A. 2002;99:413-418.
44. Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain(null) mice. Blood. 2005;106:1565-1573.
45. Takenaka K, Prasolava TK, Wang JC, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007;8:1313-1323.
46. Nakamura T, Miyakawa Y, Miyamura A, et al. A novel nonpeptidyl human c-MpL activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006;107:4300-4307.
47. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A. 2000;97:2803-2808.
48. 3, in a murine model for Glanzmann thrombasthenia. Blood. 2005;106:2671-2679.
49. Peeters K, Salles II, Hoylaerts MF, Deckmyn H, Van Geet C, Freson K. Thrombopoietic effect of VPAC1 inhibition in murine and human thrombopoiesis. J Thromb Haemost. 2009;7:PP-WE-085.